US 7,321,000 B2 | ||
Ophthalmic composition containing N-acetyl-cysteine for the treatment of dry-eye syndrome | ||
Enrico Boldrini, Pisa (Italy); Marco Fabrizio Saettone, Pisa (Italy); Patrizia Chetoni, Pisa (Italy); Susi Burgalassi, Pisa (Italy); and Boris Giannaccini, Pisa (Italy) | ||
Assigned to Farmigea S.p.A., Pisa (Italy) | ||
Appl. No. 10/484,241 PCT Filed Jul. 22, 2002, PCT No. PCT/IT02/00481 § 371(c)(1), (2), (4) Date Jun. 30, 2004, PCT Pub. No. WO03/011249, PCT Pub. Date Feb. 13, 2003. |
||
Claims priority of application No. RM2001A0438 (IT), filed on Jul. 23, 2001. | ||
Prior Publication US 2004/0248847 A1, Dec. 09, 2004 | ||
Int. Cl. A61K 31/195 (2006.01) |
U.S. Cl. 514—566 [514/912] | 8 Claims |
1. An ophthalmic composition based on acetylcysteine for administration in eyedrops, containing from 3 to 5% by weight of N-acetyl-cysteine neutralized with from 9 to 15% by weight of base DEAE-dextrane and having a physiologically acceptable osmolarity of less than 320 mOsm/kg. |